On 2 June 2023, Summit Pharmaceuticals International, a biopharmaceutical company, and start-up EVerZom signed an exclusive distribution agreement in Japan.
EVerZom is a start-up specialising in biopharmaceuticals. It is developing a process that can be adapted on a large scale to stimulate the release of extracellular vesicles, which have the capacity to regenerate damaged tissue. This innovation opens up new prospects in the field of tissue regeneration.
Summit Pharmaceuticals is a Japanese biopharmaceutical company specialising in the bioproduction of extracellular vesicles. Summit Pharmaceuticals' position as a major player and expert in the Japanese market guarantees EVerZom high-quality monitoring and R&D support in various fields.
SPI is committed to working with EVerZom to further promote and develop exosome research in the Japanese market.
Read the press release
Find out more about EVerZom
